Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk.1 This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal. Metamucil and Dr. Michael Roizen, Chairman of the Wellness Institute at Cleveland Clinic and host of the upcoming PBS series, “Younger You,” have joined to present the “Five Things Every American Needs to Do to Lower Their Cholesterol” to encourage Americans to lead a proactive lifestyle with small modifications and dietary changes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/metamucil/48409/
An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk.1 This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal. Metamucil and Dr. Michael Roizen, Chairman of the Wellness Institute at Cleveland Clinic and host of the upcoming PBS series, “Younger You,” have joined to present the “Five Things Every American Needs to Do to Lower Their Cholesterol” to encourage Americans to lead a proactive lifestyle with small modifications and dietary changes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/metamucil/48409/
The CIGNA Health Awareness Tour Mobile Learning Lab is an experiential exhibit on 18 wheels that helps to raise awareness and understanding of traditional and non-traditional influencers of health.
Many health awareness efforts seek to increase individual understanding of the importance of key “numbers” or medical indicators of health, such as blood pressure and cholesterol levels. While these measures are important, the Mobile Learning Lab takes awareness to a new level, challenging guests to look at health more holistically.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46644-CIGNA-Mobile-Learning-Lab/
When searching the pharmacy shelves, people looking for help to support healthy good cholesterol with a dietary supplement niacin may inaccurately associate the ingredient nicotinic acid with smoking cessation because it sounds like nicotine, warns leading cardiologist, Dr. Carl Lavie, Medical Director of Cardiac Rehabilitation and Prevention at the John Ochsner Heart and Vascular Institute, New Orleans, LA. In fact, nicotinic acid is the only form of dietary supplement niacin that is clinically proven to support good cholesterol, also known as high-density lipoprotein cholesterol, or HDL.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58806-upsher-smith-cardiologist-advice-niacin-nicotinic-acid-flush-free
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Beginning in mid-March, the AARP/Walgreens Wellness Tour will once again travel the country, embarking on a ten-month tour to provide an expected $14 million worth of free health tests. The national mobile tour will conduct free health-testing events in communities throughout the United States and Puerto Rico. The free tests—which include total cholesterol levels, blood pressure, bone density, glucose levels, waist circumference and body mass index—are valued at $100 per person and may help provide adults with a critical foundation for early disease detection and prevention.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/walgreens/48029/
